News Preview
Experimental cancer vaccine cuts melanoma recurrence risk by 42%: Study
An experimental cancer vaccine has shown promising results in reducing the risk of melanoma recurrence by 42%, according to a new study published in the New England Journal of Medicine.
The vaccine, called MAGE-A3, was found to be effective in patients with stage III melanoma, a type of skin cancer that has spread to nearby lymph nodes.
The study, which involved over 1,300 patients from 29 countries, found that those who received the vaccine had a lower risk of their cancer returning compared to those who received a placebo.
While this is a significant development in cancer treatment, it may not have an immediate impact on seafarers, as melanoma is not typically associated with maritime occupations.
Want to stay up to date with the world events at sea or at home?
Explore Navvyx News - the best News app for seafarers.